Manufacturers of glucagon-like peptide-1 (GLP-1) medications, including Eli Lilly and Novo Nordisk, have collectively paid more than $270 million to over 250,000 health care providers since 2018 to encourage prescriptions of drugs such as Ozempic, Wegovy, and Zepbound. This level of promotional spending is the highest recorded for any class of prescription medications during that period, according to publicly available federal data.

The substantial investment in outreach coincides with a surge in patient demand driven by widespread television advertising and word of mouth. The market for these medications has rapidly expanded beyond their initial diabetes treatment indications to include obesity and cardiovascular risk management. In 2025 alone, sales reached record highs, with Eli Lilly’s Mounjaro generating $63 billion and Novo Nordisk’s Ozempic and Wegovy accounting for $59 billion.

Pharmaceutical companies have enlisted key opinion leaders—physicians who frequently receive honoraria—to engage with peers through clinical presentations and promotional events often held in upscale venues nationwide. These interactions typically emphasize the drugs’ efficacy for weight loss and chronic disease management, though critics point out that discussions may understate potential long-term risks. Among the concerns highlighted by the U.S. Food and Drug Administration (FDA) black box warnings are side effects such as nausea, constipation, and the possible risk of thyroid cancer, along with the potential for weight regain after discontinuing treatment.

Physicians involved in these promotional activities argue that their role is primarily educational, aiming to reduce uncertainty and skepticism around treating obesity as a chronic condition requiring long-term pharmacotherapy. They contend that increased awareness and familiarity with GLP-1 therapies help address gaps in medical education and practitioner hesitancy to prescribe newly approved, often costly drugs.

Nevertheless, some medical experts and advocacy groups warn that financial relationships between doctors and drug manufacturers may lead to conflicts of interest and prescribing patterns that favor continuous, expensive treatment without sufficient long-term safety data. They express particular caution regarding the use of GLP-1 drugs in populations such as the elderly and individuals with eating disorders, where risks may be amplified.

Federal data also reveal that many influential practitioners and leaders of medical societies receive substantial payments, which extend to funding of continuing medical education programs and advisory board participation. This raises ongoing questions about the impartiality of clinical guidelines and educational content shaped by industry support.

Views among experts diverge on the implications of these financial ties. Some emphasize transparency measures and the role of scientific rigor in ensuring appropriate use, while others highlight the subtle influence such payments can exert on prescribing behavior and the potential promotion of long-term medication regimens despite unanswered questions about metabolic effects of weight cycling.

Overall, the complex interplay between pharmaceutical marketing, physician education, and patient care surrounding GLP-1 weight-loss drugs underscores a critical moment in obesity treatment, with far-reaching implications for clinical practice and healthcare spending.